<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To assess the effect of <z:chebi fb="0" ids="6801">metformin</z:chebi> intake on <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence and mortality </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Original articles in English published until June 15, 2012 were searched for in electronic databases (MEDLINE, ISI Web of Science and EMBASE databases) and relevant reviews were examined </plain></SENT>
<SENT sid="2" pm="."><plain>Meta-analysis was applied to calculate the summary relative risk (SRR) and their 95% confidence intervals (95% CI) </plain></SENT>
<SENT sid="3" pm="."><plain>Sensitivity analysis was conducted to assess the robustness of the pooled estimator </plain></SENT>
<SENT sid="4" pm="."><plain>The risk of publication bias was assessed by the Egger regression asymmetry test </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: According to the eligibility criteria, 37 studies comprising 1,535,636 participants, were selected in terms of intervention and data of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence or mortality </plain></SENT>
<SENT sid="6" pm="."><plain>Among <z:chebi fb="0" ids="6801">metformin</z:chebi> users compared with non-users, the SRR for overall-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence was 0.73 (95% CI, 0.64-0.83) and that for mortality was 0.82 (95% CI, 0.76-0.89) </plain></SENT>
<SENT sid="7" pm="."><plain>The risk reductions for liver, pancreatic, colorectal and <z:hpo ids='HP_0003002'>breast cancer</z:hpo> incidence were 78%, 46%, 23% and 6%, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Also, <z:chebi fb="0" ids="6801">metformin</z:chebi> can reduce the mortality of <z:hpo ids='HP_0002896'>liver cancer</z:hpo> (SRR, 0.23; 95% CI, 0.09-0.60) and <z:hpo ids='HP_0003002'>breast cancer</z:hpo> (SRR, 0.63; 95% CI, 0.40-0.99) </plain></SENT>
<SENT sid="9" pm="."><plain>No statistically significant association between <z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> incidence was found </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="6801">Metformin</z:chebi> can reduce the incidence of overall <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, <z:hpo ids='HP_0002896'>liver cancer</z:hpo>, <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo>, <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and <z:hpo ids='HP_0003002'>breast cancer</z:hpo> as well as the mortality of overall <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, <z:hpo ids='HP_0002896'>liver cancer</z:hpo> and <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>No beneficial effect on <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> incidence was found for meformin intake in the meta-analysis </plain></SENT>
</text></document>